Abstract:Importance: Many interventions implemented for multi-visit patients (MVP) have been developed to address patient-centric needs of these individuals and reduce unplanned care for ambulatory-sensitive conditions. More rigorous research is needed to better understand the impact of these interventions on changes in care utilization including unplanned care. Objective: To evaluate the impact of the Enhanced Care Program (ECP), a payer-provider collaborative model, on unplanned care use and cost of care. Design: Using propensity methods, a comparison group was constructed using insurer membership files. Comparisons were performed using a difference-in-differences analysis. Participants: Patients enrolled in ECP through December 2019 were considered eligible for the study (n = 357). All patients had five or more ED visits in the past year or two or more inpatient hospitalizations in the past year prior to enrollment. Exposures: ECP is a high-intensity outpatient intervention intended to reduce avoidable unplanned care such as ED visits and inpatient hospital stays through home visits, chronic/acute disease management, and intensive care coordination. Main measures: The primary outcomes of interest were events per 100 members per year of ED use with return to home, unplanned inpatient and observational status admissions, and unplanned behavioral health inpatient admission, and cost of care per member per month. Key results: Overall total unplanned care encounters were significantly reduced with a difference-in-difference of 320 unplanned care encounters per 100 members per year in the intervention group (p < 0.05). The ECP group showed statistically significant decreases in costs of unplanned ED, unplanned observation admission, and unplanned inpatient behavioral medicine costs, but statistically significant increases in overall pharmacy costs and lab costs. Changes in total costs of care for the ECP group were not statistically different than the control group (p = 0.55). Conclusions: ECP showed significant reduction of unplanned care for MVP patients.

Episode-Based Cost Sharing to Prospectively Guarantee Patients’ Out-of-Pocket Costs

Inequities in Unexpected Cost-Sharing for Preventive Care in the United States

Copay accumulators: Shifting costs of oncology drugs from plans to patients

Linking Cost Sharing to Value: An Unrivaled Yet Unrealized Public Health Opportunity

Why Cost Sharing Alone Will Not Fix Health Care Costs

It Takes 2 to Tango. Setting Out the Conditions in Which Performance-Based Risk-Sharing Arrangements Work for Both Parties

Episode-Based Payment and Direct Employer Purchasing of Healthcare Services: Recent Bundled Payment Innovations and the Geisinger Health System Experience

A Path to Risk: Critical Elements of a Structured Approach

Patient Cost-Sharing and Hospitalization Offsets in the Elderly

What are the risks of clinic-backed payment plans?

Editorial Commentary: Increasing Patient Out-of-Pocket Expense Does Not Increase Value of Outpatient Surgery

Cost sharing in managed care and the ethical question of business purpose

Strategy and risk sharing in hospital-postacute care integration

The Case for Capitation

Exploring patient perspectives on the impact of resuming cost sharing: a qualitative analysis

Reference Pricing for Healthcare Services

The impact of telehealth cost-sharing on healthcare utilization: Evidence from high-deductible health plans

Better Care, Same Cost - Reducing Unplanned Care for Multi-visit Patients: A Payer-Provider Model

Analysis of a pharmaceutical risk sharing agreement based on the purchaser's total budget

Predictive Tools in Charity Care—Revenue vs Access

A Rule-Based Solution to Opaque Medical Billing in the U.S.